A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 4 sites in France. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.
Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 18th largest by enrollment, is one of 4 that started in 2012, is one of 12 in phase 3, and was the 12th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:
Duke University · Sites in United States, Germany, Italy and 1 more country
Ages 2–21
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 2 · Phase 3 12 · Phase 4 2
First in 2004; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 52 across the 21 interventional studies. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 7 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
17 studies in Arthritis, Juvenile by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 17 studies in Arthritis, Juvenile by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2012, is one of 10 in phase 3, and was the 10th registered.
Hoffmann-La Roche’s Arthritis, Juvenile studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing tocilizumab in Arthritis, Juvenile, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 17 in Arthritis, Juvenile:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients will continue to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tocilizumab [RoActemra/Actemra]
Drug page: Tocilizumab
8 mg/kg iv every 4 weeks, 104 weeks
Number of Participants With Any Adverse Events and Any Serious Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.
Time frame: Approximately 2 years
Number of Participants With Adverse Events of Special Interest
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. The AEs of special interests included gingival bleeding, tooth abscess, acarodermatitis, ear infection, gastroenteritis, herpes zoster ophthalmic, lice infestation, nasopharyngitis, oral fungal infection, oral herpes, pharyngitis, rhinitis, sinusitis, tonsillitis, tracheitis, tracheobronchitis, urinary tract infection, menorrhagia, asthma, epistaxis, and hematoma.
Time frame: Approximately 2 years
Number of Participants With Adverse Events Related to Tocilizumab
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. Relatedness of any AEs was reported as possibly related, probably related, or remotely related to TCZ.
Time frame: Approximately 2 years
Mean Exposure to Study Treatment
Participants received TCZ for Week 104 or when TCZ was commercially available for pcJIA participants, whichever comes first in France. The mean TCZ exposure (time from first to last administration) was reported.
Time frame: Approximately 2 years
Mean Duration of Study Follow-Up
The participants were followed-up from Day 1 to last visit date (approximately 2 years). Mean time for which participants were followed up in the study was reported.
Time frame: Approximately 2 years
Number of Participants With AEs Leading to TCZ Modification, AEs Leading to Death, Anaphylaxis or Serious Hypersensitivity and Deaths
Number of participants with AEs leading to TCZ modification, AEs leading to death, anaphylaxis or serious hypersensitivity, and deaths were reported.
Time frame: Approximately 2 years
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
Clinically significant abnormal parameters included eosinophil count, alanine aminotransferase, total bilirubin, and protein and blood in urine. Number of participants with these abnormal lab parameters was reported.
Time frame: Approximately 2 years
Number of Participants With Abnormality in Physical Examinations
Participants with abnormal physical examinations of ear, nose and throat (asthma); extremities (synovitis, sequelae with flexion of the 5th right proximal interphalangeal joint, hallux valgus, deviations of metatarsophalangeal joints, and callus under metatarsal head); lung (mild bronchospasm); skin (vitiligo and hematoma, fatty subcutaneous infiltration on the neck, cutaneous eruption, and scalp pediculosis); and musculoskeletal system (discomfort in right hip) were reported.
Time frame: Approximately 2 years
Number of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology Response 50/70
The Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) is comprised of six components: Maximum number of joints with active arthritis; Number of joints with limitation of movement; Erythrocyte Sedimentation Rate (ESR) and/or C-reactive Protein (CRP); Childhood Health Assessment Questionnaire-Disease Index (CHAQ-DI) graded on 4-point scales \[0 = without any difficulty and 3 = unable to do\] of 30 items grouped into 8 domains of physical function; Physician's global assessment of disease activity and Participant's global assessment of overall well-being (both assessed on a 0 to 100 mm Visual Analogue Scale \[VAS\], where score 0 = inactive arthritis and 100 = very active arthritis). A JIA ACR50/70 response is defined as improvement in at least three of the six core components by at least 50 percent (%), or 70%, respectively and no more than one of the remaining core components worsening by more than 30%.
Time frame: Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Number of Participants With Inactive Disease
Inactive disease was defined as: 1) No joints with active arthritis (no swollen, painful and lack of motion joints), 2) No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, 3) No active uveitis, 4) ESR and/or CRP within normal range, and 5) No disease activity according to Physician's global assessment of disease activity (\<= 10 millimeters \[mm\] on a VAS). The participant's treating physician provided a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale where score 0 represented 'arthritis inactive' (i.e., symptom-free and no arthritis symptoms) and score 100 represented 'arthritis very active'.
Time frame: Weeks 24, 36, 48, 72, and 108
Number of Participants Achieving Clinical Remission
Clinical remission was defined as inactive disease observed for at least 6 continuous months. Clinical remission was defined as per medication uptake as: Level 1 (clinical remission on medication), Level 2 (clinical remission off oral corticosteroid medication \[still on TCZ\]), Level 3 (clinical remission off both oral corticosteroid and methotrexate medication \[still on TCZ\]), and Level 4 (clinical remission off all anti-inflammatory medications \[still on TCZ\]). Number of participants at each clinical remission level was reported.
Time frame: Weeks 24, 36, 48, 72, and 108
Number of Participants With a Minimally Important Improvement in the Childhood Health Assessment Questionnaire-Disability Index
The CHAQ-DI included questions on dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. The disability index (DI) of the original CHAQ was graded on 4-point categorical scales of 30 items grouped into 8 domains of physical function. The highest scoring item in each domain determined the score for that domain. The score for the disability index was the mean of domain scores ranging from 0 to 3 (0 = without any difficulty and 3 = unable to do) with higher scores meaning higher disability. Minimally important improvement in CHAQ-DI was defined as a change from baseline of WA19977 core study (Day 1/Visit 1) \>=0.13 at each visit.
Time frame: Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Number of Joints With Limitation of Motion
The most frequent symptom reported by most participants was a limitation of motion (LOM) of joints and it was determined by physical examination. The mean joints with limitation of motion were reported.
Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Number of Joints With Active Range of Motion
The active range of motion joints was counted by physical examination and mean joints was reported.
Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Number of Swollen Joints
The swollen joints was counted by physical examination and mean swollen joints were reported.
Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Number of Painful Joints
The painful joints were counted by physical examination and mean painful joints was reported.
Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Physician's Global Assessment of Disease Activity
The Physician's global assessment of disease activity was recorded on a 0 to 100 mm horizontal VAS where score 0 represented 'arthritis inactive' (i.e., symptom-free and no arthritis symptoms) and score 100 represented 'arthritis very active' (higher score indicate worsening of disease).
Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Parent/Patient's Global Assessment of Disease Activity
Parent/patient global assessment of disease activity was performed using 0 to 100 mm VAS, and higher the score of VAS, worse the disease status (0= absence of activity or sign or symptom; 100= maximal activity or signs or symptoms). No disease activity was defined as VAS \<=10 mm.
Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
Parent/Patient's Discomfort Index (Pain)
Participants or parents rated participant's pain by placing a horizontal line on a VAS of 0 (no pain) - 100 mm (unbearable pain). To describe the pain, a cut-off at 10 mm was used, and VAS \<10 mm was defined as no pain.
Time frame: Baseline (Day 1), Weeks 12, 24, 36, 48, 60, 72, 84, and 108
A total of seven participants who completed the core study WA19977 were enrolled in this extension study conducted from 13 February 2012 to 15 January 2014 at four centers in France.
| Milestone | Tocilizumab (8 mg/kg) |
|---|---|
| Started | 7 |
| Completed | 7 |
| Not completed | 0 |
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An serious adverse event (SAE) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| Any AEs | 7 |
| Any SAEs | 0 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. The AEs of special interests included gingival bleeding, tooth abscess, acarodermatitis, ear infection, gastroenteritis, herpes zoster ophthalmic, lice infestation, nasopharyngitis, oral fungal infection, oral herpes, pharyngitis, rhinitis, sinusitis, tonsillitis, tracheitis, tracheobronchitis, urinary tract infection, menorrhagia, asthma, epistaxis, and hematoma.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| Gingival bleeding | 2 |
| Tooth abscess | 2 |
| Acarodermatitis | 1 |
| Ear infection | 1 |
| Gastroenteritis | 1 |
| Herpes zoster ophthalmic | 1 |
| Lice infestation | 1 |
| Nasopharyngitis | 1 |
| Oral fungal infection | 1 |
| Oral herpes | 1 |
| Pharyngitis | 1 |
| Rhinitis | 1 |
| Sinusitis | 1 |
| Tonsillitis | 1 |
| Tracheitis | 1 |
| Tracheobronchitis | 1 |
| Urinary tract infection | 1 |
| Menorrhagia | 1 |
| Asthma | 1 |
| Epistaxis | 1 |
| Hematoma | 1 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. Relatedness of any AEs was reported as possibly related, probably related, or remotely related to TCZ.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| AEs possibly related to TCZ | 5 |
| AEs probably related to TCZ | 2 |
| AEs remotely related to TCZ | 1 |
Participants received TCZ for Week 104 or when TCZ was commercially available for pcJIA participants, whichever comes first in France. The mean TCZ exposure (time from first to last administration) was reported.
| Months | Tocilizumab (8 mg/kg) |
|---|---|
| Mean Exposure to Study Treatment | 17.08 ± 1.55 |
The participants were followed-up from Day 1 to last visit date (approximately 2 years). Mean time for which participants were followed up in the study was reported.
| Months | Tocilizumab (8 mg/kg) |
|---|---|
| Mean Duration of Study Follow-Up | 21.08 ± 1.64 |
Number of participants with AEs leading to TCZ modification, AEs leading to death, anaphylaxis or serious hypersensitivity, and deaths were reported.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| AEs leading to TCZ modification | 2 |
| AEs leading to death | 0 |
| Anaphylaxis or serious hypersensitivity | 0 |
| Death | 0 |
Clinically significant abnormal parameters included eosinophil count, alanine aminotransferase, total bilirubin, and protein and blood in urine. Number of participants with these abnormal lab parameters was reported.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| Eosinophil count | 1 |
| Alanine aminotransferase | 1 |
| Total bilirubin | 1 |
| Protein and blood in urine | 2 |
Participants with abnormal physical examinations of ear, nose and throat (asthma); extremities (synovitis, sequelae with flexion of the 5th right proximal interphalangeal joint, hallux valgus, deviations of metatarsophalangeal joints, and callus under metatarsal head); lung (mild bronchospasm); skin (vitiligo and hematoma, fatty subcutaneous infiltration on the neck, cutaneous eruption, and scalp pediculosis); and musculoskeletal system (discomfort in right hip) were reported.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| Ear, nose and throat | 1 |
| Extremities | 1 |
| Lung | 1 |
| Musculoskeletal system | 1 |
| Skin | 3 |
The Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) is comprised of six components: Maximum number of joints with active arthritis; Number of joints with limitation of movement; Erythrocyte Sedimentation Rate (ESR) and/or C-reactive Protein (CRP); Childhood Health Assessment Questionnaire-Disease Index (CHAQ-DI) graded on 4-point scales \[0 = without any difficulty and 3 = unable to do\] of 30 items grouped into 8 domains of physical function; Physician's global assessment of disease activity and Participant's global assessment of overall well-being (both assessed on a 0 to 100 mm Visual Analogue Scale \[VAS\], where score 0 = inactive arthritis and 100 = very active arthritis). A JIA ACR50/70 response is defined as improvement in at least three of the six core components by at least 50 percent (%), or 70%, respectively and no more than one of the remaining core components worsening by more than 30%.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| JIA ACR50, Week 12 (n = 5) | 1 |
| JIA ACR50, Week 24 (n = 5) | 2 |
| JIA ACR50, Week 36 (n = 6) | 1 |
| JIA ACR50, Week 48 (n = 5) | 1 |
| JIA ACR50, Week 60 (n = 5) | 0 |
| JIA ACR50, Week 72 (n = 2) | 0 |
| JIA ACR50, Week 84 (n = 1) | 1 |
| JIA ACR50, Week 108 (n = 6) | 2 |
| JIA ACR70, Week 12 (n = 5) | 4 |
| JIA ACR70, Week 24 (n = 5) | 3 |
| JIA ACR70, Week 36 (n = 6) | 5 |
| JIA ACR70, Week 48 (n = 5) | 4 |
| JIA ACR70, Week 60 (n = 5) | 5 |
| JIA ACR70, Week 72 (n = 2) | 2 |
| JIA ACR70, Week 84 (n = 1) | 0 |
| JIA ACR70, Week 108 (n = 6) | 4 |
Inactive disease was defined as: 1) No joints with active arthritis (no swollen, painful and lack of motion joints), 2) No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, 3) No active uveitis, 4) ESR and/or CRP within normal range, and 5) No disease activity according to Physician's global assessment of disease activity (\<= 10 millimeters \[mm\] on a VAS). The participant's treating physician provided a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale where score 0 represented 'arthritis inactive' (i.e., symptom-free and no arthritis symptoms) and score 100 represented 'arthritis very active'.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| Week 24 (n = 6) | 1 |
| Week 36 (n = 7) | 1 |
| Week 48 (n = 6) | 1 |
| Week 72 (n = 4) | 1 |
| Week 108 (n = 7) | 1 |
Clinical remission was defined as inactive disease observed for at least 6 continuous months. Clinical remission was defined as per medication uptake as: Level 1 (clinical remission on medication), Level 2 (clinical remission off oral corticosteroid medication \[still on TCZ\]), Level 3 (clinical remission off both oral corticosteroid and methotrexate medication \[still on TCZ\]), and Level 4 (clinical remission off all anti-inflammatory medications \[still on TCZ\]). Number of participants at each clinical remission level was reported.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| Week 24, Remission level 1 (n = 7) | 1 |
| Week 36, Remission level 1 (n = 6) | 5 |
| Week 48, Remission level 1 (n = 6) | 1 |
| Week 72, Remission level 1 (n = 4) | 1 |
| Week 108, Remission level 1 (n = 7) | 1 |
The CHAQ-DI included questions on dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. The disability index (DI) of the original CHAQ was graded on 4-point categorical scales of 30 items grouped into 8 domains of physical function. The highest scoring item in each domain determined the score for that domain. The score for the disability index was the mean of domain scores ranging from 0 to 3 (0 = without any difficulty and 3 = unable to do) with higher scores meaning higher disability. Minimally important improvement in CHAQ-DI was defined as a change from baseline of WA19977 core study (Day 1/Visit 1) \>=0.13 at each visit.
| participants | Tocilizumab (8 mg/kg) |
|---|---|
| Week 12 (n=7) | 5 |
| Week 24 (n=7) | 5 |
| Week 36 (n=7) | 6 |
| Week 48 (n=7) | 5 |
| Week 60 (n=7) | 6 |
| Week 72 (n=3) | 2 |
| Week 84 (n=1) | 0 |
| Week 108 (n=7) | 6 |
The most frequent symptom reported by most participants was a limitation of motion (LOM) of joints and it was determined by physical examination. The mean joints with limitation of motion were reported.
| joints | Tocilizumab (8 mg/kg) |
|---|---|
| Day 1 (n=7) | 11.4 ± 14.3 |
| Week 12 (n=7) | 9.4 ± 11.9 |
| Week 24 (n=6) | 6.7 ± 8.4 |
| Week 36 (n=7) | 8.1 ± 9.5 |
| Week 48 (n=7) | 8.6 ± 10.5 |
| Week 60 (n=7) | 10.3 ± 14.8 |
| Week 72 (n=4) | 8.5 ± 16.3 |
| Week 84 (n=1) | 31.0 ± NA |
| Week 108 (n=7) | 10.6 ± 13.4 |
The active range of motion joints was counted by physical examination and mean joints was reported.
| joints | Tocilizumab (8 mg/kg) |
|---|---|
| Day 1 (n=7) | 2.3 ± 2.5 |
| Week 12 (n=7) | 1.4 ± 2.3 |
| Week 24 (n=6) | 2.2 ± 2.2 |
| Week 36 (n=7) | 1.3 ± 1.8 |
| Week 48 (n=7) | 2.0 ± 1.9 |
| Week 60 (n=7) | 2.0 ± 2.2 |
| Week 72 (n=4) | 0.3 ± 0.5 |
| Week 84 (n=1) | 0.0 ± NA |
| Week 108 (n=7) | 1.1 ± 1.2 |
The swollen joints was counted by physical examination and mean swollen joints were reported.
| joints | Tocilizumab (8 mg/kg) |
|---|---|
| Day 1 (n=7) | 1.6 ± 2.1 |
| Week 12 (n=7) | 1.0 ± 2.2 |
| Week 24 (n=6) | 1.0 ± 1.7 |
| Week 36 (n=7) | 0.9 ± 1.5 |
| Week 48 (n=7) | 1.9 ± 1.8 |
| Week 60 (n=7) | 1.7 ± 2.2 |
| Week 72 (n=4) | 0.3 ± 0.5 |
| Week 84 (n=1) | 0.0 ± NA |
| Week 108 (n=7) | 0.7 ± 1.3 |
The painful joints were counted by physical examination and mean painful joints was reported.
| joints | Tocilizumab (8 mg/kg) |
|---|---|
| Day 1 (n=7) | 1.9 ± 2.3 |
| Week 12 (n=7) | 0.6 ± 0.8 |
| Week 24 (n=6) | 2.0 ± 2.8 |
| Week 36 (n=7) | 0.7 ± 1.0 |
| Week 48 (n=7) | 0.9 ± 1.1 |
| Week 60 (n=7) | 0.7 ± 1.0 |
| Week 72 (n=4) | 0.5 ± 1.0 |
| Week 84 (n=1) | 0.0 ± NA |
| Week 108 (n=7) | 2.0 ± 4.0 |
The Physician's global assessment of disease activity was recorded on a 0 to 100 mm horizontal VAS where score 0 represented 'arthritis inactive' (i.e., symptom-free and no arthritis symptoms) and score 100 represented 'arthritis very active' (higher score indicate worsening of disease).
| millimeter (mm) | Tocilizumab (8 mg/kg) |
|---|---|
| Day 1 (n=7) | 8.6 ± 7.7 |
| Week 12 (n=6) | 4.2 ± 6.4 |
| Week 24 (n=7) | 9.3 ± 12.2 |
| Week 36 (n=7) | 6.7 ± 6.9 |
| Week 48 (n=7) | 3.7 ± 3.6 |
| Week 60 (n=7) | 4.0 ± 3.4 |
| Week 72 (n=4) | 2.8 ± 4.3 |
| Week 84 (n=1) | 4.0 ± NA |
| Week 108 (n=7) | 6.6 ± 7.1 |
Parent/patient global assessment of disease activity was performed using 0 to 100 mm VAS, and higher the score of VAS, worse the disease status (0= absence of activity or sign or symptom; 100= maximal activity or signs or symptoms). No disease activity was defined as VAS \<=10 mm.
| mm | Tocilizumab (8 mg/kg) |
|---|---|
| Day 1 (n=7) | 14.9 ± 27.5 |
| Week 12 (n=7) | 8.0 ± 12.2 |
| Week 24 (n=7) | 12.7 ± 23.3 |
| Week 36 (n=7) | 3.9 ± 6.8 |
| Week 48 (n=7) | 10.1 ± 17.4 |
| Week 60 (n=7) | 7.4 ± 8.3 |
| Week 72 (n=3) | 0.3 ± 0.6 |
| Week 84 (n=1) | 73.0 ± NA |
| Week 108 (n=7) | 12.1 ± 17.8 |
Participants or parents rated participant's pain by placing a horizontal line on a VAS of 0 (no pain) - 100 mm (unbearable pain). To describe the pain, a cut-off at 10 mm was used, and VAS \<10 mm was defined as no pain.
| mm | Tocilizumab (8 mg/kg) |
|---|---|
| Day 1 (n=7) | 15.0 ± 27.2 |
| Week 12 (n=7) | 5.6 ± 7.7 |
| Week 24 (n=7) | 7.7 ± 11.1 |
| Week 36 (n=7) | 3.0 ± 3.1 |
| Week 48 (n=7) | 12.9 ± 18.5 |
| Week 60 (n=7) | 6.4 ± 7.3 |
| Week 72 (n=3) | 0.7 ± 0.6 |
| Week 84 (n=1) | 51.0 ± NA |
| Week 108 (n=7) | 5.1 ± 9.0 |
Collected over Approximately 2 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab (8 mg/kg) | — | 0/7 (0%) | 7/7 (100%) |
| Event | Tocilizumab (8 mg/kg) |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/7 |
| Abdominal painGastrointestinal disorders | 2/7 |
| Gingival bleedingGastrointestinal disorders | 2/7 |
| Tooth abscessInfections and infestations | 2/7 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/7 |
| Von Willebrand's diseaseCongenital, familial and genetic disorders | 1/7 |
| ChalazionEye disorders | 1/7 |
| ConjunctivitisEye disorders | 1/7 |
| Dental cariesGastrointestinal disorders | 1/7 |
| Gastrointestinal disorderGastrointestinal disorders | 1/7 |
The intent-to-treat (ITT) population included all the participants who had at least one efficacy assessment.
| Age, Customized(participants) | Tocilizumab (8 mg/kg) |
|---|---|
| 2 to 11 years | 3 |
| 12 to 17 years | 2 |
| 18 to 64 years | 2 |
| Sex: Female, Male(Participants) | Tocilizumab (8 mg/kg) |
|---|---|
| Female | 7 |
| Male | 0 |
The record gives a start of Feb 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab